Donal P. McLornan
A5017537622- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Eosinophilic Disorders and Syndromes
- Hematopoietic Stem Cell Transplantation
- Kruppel-like factors research
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Hemoglobinopathies and Related Disorders
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Platelet Disorders and Treatments
- Renal Transplantation Outcomes and Treatments
- SARS-CoV-2 and COVID-19 Research
- Cell death mechanisms and regulation
- Mesenchymal stem cell research
- Mast cells and histamine
- Polyomavirus and related diseases
- Renal Diseases and Glomerulopathies
- Protein Degradation and Inhibitors
- Biomedical Ethics and Regulation
- Lymphoma Diagnosis and Treatment
University College London
2020-2025
University College London Hospitals NHS Foundation Trust
2022-2025
University College Hospital
2020-2025
Guy's and St Thomas' NHS Foundation Trust
2015-2024
King's College Hospital
2013-2024
National Health Service
2015-2024
Royal London Hospital
2022-2024
King's College London
2014-2023
Azienda Ospedaliero-Universitaria Careggi
2023
Vanderbilt University
2023
Purpose We evaluated the efficacy and safety of momelotinib, a potent selective Janus kinase 1 2 inhibitor (JAKi), compared with ruxolitinib, in JAKi-naïve patients myelofibrosis. Patients Methods (N = 432) high risk or intermediate-2 symptomatic intermediate-1 myelofibrosis were randomly assigned to receive 24 weeks treatment momelotinib 200 mg once daily ruxolitinib 20 twice day (or per label), after which all could open-label momelotinib. The primary end point was ≥ 35% reduction spleen...
Abstract In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 received advanced cellular therapies, 2524 of which CAR-T treatments, an additional 3245 DLI. Changes compared to the previous year treatment (+35%), +5.4%, autologous +3.9%, more pronounced non-malignant disorders. Main indications for myeloid malignancies 10,745 (58%), lymphoid 5127 (28%) disorders 2501 (13%). 22,129 (90%) solid tumors 1635 (7%)....
Abstract In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 received advanced cellular therapies, 3205 of which CAR-T. An additional 2854 DLI. Changes compared to the previous year an increase CAR-T treatments (+27%) decrease (−4.0%) autologous (−1.7%). Main indications for myeloid malignancies (10,433; 58.4%), lymphoid (4,674; 26.2%) non-malignant disorders (2572; 14.4%). lymphomas (7897; 32.9%), PCD...
The guideline group was selected to be representative of UK-based medical experts with an interest in myeloproliferative neoplasms and eosinophilia. PubMed EMBASE were searched systematically for publications English until August 2015 using the key words eosinophilia, hypereosinophilia, eosinophilic leukaemia HES. writing produced draft guideline, which subsequently revised by consensus members General Haematology Haemato-oncology Task Forces British Committee Standards (BCSH). then reviewed...
The impact of Janus kinase (JAK) 1/2 inhibitor therapy before allogeneic hematopoietic cell transplantation (HCT) has not been studied in a large cohort myelofibrosis (MF). In this retrospective multicenter study, we analyzed outcomes patients who underwent HCT for MF with prior exposure to JAK1/2 inhibitors. One hundred consecutive from participating centers were analyzed, and based on clinical status response inhibitors at the time HCT, stratified into 5 groups: (1) improvement (n = 23),...
In a multicenter collaboration, we carried out T cell-replete, peripheral blood stem cell (PBSC) transplantations from related, HLA-haploidentical donors with reduced-intensity conditioning (RIC) and post-transplantation cyclophosphamide (Cy) as graft-versus-host disease (GVHD) prophylaxis in 55 patients high-risk hematologic disorders. Patients received 2 doses of Cy 50 mg/kg i.v. on days 3 4 after infusion PBSC (mean, 6.4 × 10(6)/kg CD34(+) cells; mean, 2.0 10(8)/kg CD3(+) cells). The...
New transplant approaches are urgently needed for patients with refractory severe aplastic anemia (SAA) who lack a matched sibling or unrelated donor (UD) have failed UD cord blood transplant. Patients SAA at risk of later clonal evolution to myelodysplastic syndrome and acute leukemia. We report our pilot findings haploidentical hematopoietic stem cell transplantation (haploHSCT) using uniform reduced-intensity conditioning postgraft high-dose cyclophosphamide in 8 rejected prior Six...
Reliable detection of JAK2-V617F is critical for accurate diagnosis myeloproliferative neoplasms (MPNs); in addition, sensitive mutation-specific assays can be applied to monitor disease response. However, there has been no consistent approach detection, with varying markedly performance, affecting clinical utility. Therefore, we established a network 12 laboratories from seven countries systematically evaluate nine different DNA-based quantitative PCR (qPCR) assays, including those...
This retrospective study by the European Society for Blood and Marrow Transplantation analyzed outcome of 2224 patients with myelofibrosis (MF) who underwent allogeneic stem cell transplantation (allo-SCT) between 2000 2014; 781 (35%) myeloablative conditioning (MAC) 1443 (65%) reduced-intensity (RIC). Median patient age was 52.9 years (range, 18 to 74 years) 57.5 21 76 in MAC RIC cohorts, respectively. Donor type similar: matched sibling donors (MAC, 317 [41%]; RIC, 552 [38%]) unrelated 464...
Summary Patients receiving targeted cancer treatments such as tyrosine kinase inhibitors (TKIs) have been classified in the clinically extremely vulnerable group to develop severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), including patients with chronic myeloid leukaemia (CML) taking TKIs. In addition, concerns that immunocompromised individuals solid and haematological malignancies may not mount an adequate immune response a single dose of SARS‐CoV‐2 BNT162b2 (Pfizer‐BioNTech)...
Abstract JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated 551 who received HSCT without ( n = 274) or 277) pretreatment. The overall leukocyte engraftment day 45 was 92% and significantly higher responsive than those had no lost response (94% vs. 85%, p 0.05). 1-year non-relapse mortality 22% significant difference...
Abstract Janus kinase inhibitors (JAKi) approved for myelofibrosis provide spleen and symptom improvements but do not address anemia, a negative prognostic factor. Momelotinib, an inhibitor of ACVR1/ALK2, JAK1 JAK2, demonstrated activity against symptoms, splenomegaly in the phase 3 SIMPLIFY trials. Here, we report mature overall survival (OS) leukemia-free (LFS) from both studies, retrospective analyses baseline characteristics efficacy endpoints OS associations. Survival distributions were...
Bone marrow fibrosis (BMF) is a pathological feature of myelofibrosis, with higher grades associated poor prognosis. Limited data exist on the association between outcomes and BMF changes. We present from Janus kinase (JAK) inhibitor-naive patients SIMPLIFY-1 (NCT01969838), double-blind, randomized, phase 3 study momelotinib vs ruxolitinib. Baseline week 24 bone biopsies were graded 0 to as per World Health Organization criteria. Other assessments included Total Symptom Score, spleen volume,...